Myriad Genetics
MYGN
221 hedge funds and large institutions have $1.27B invested in Myriad Genetics in 2024 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 91 increasing their positions, 74 reducing their positions, and 57 closing their positions.
1,343% more call options, than puts
Call options by funds: $4.1M | Put options by funds: $284K
23% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 74
1.71% more ownership
Funds ownership: 99.88% → 101.59% (+1.7%)
10% less funds holding
Funds holding: 246 → 221 (-25)
42% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 57
49% less capital invested
Capital invested by funds: $2.48B → $1.27B (-$1.22B)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
+$53.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$12.3M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$60M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$15.7M |
| 3 |
Millennium Management
New York
|
-$15.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.1M |
MYGN Hedge Fund Activity: Q4 2024 in Review
221 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2024, worth a combined $1.27B — down 49% from $2.48B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of MYGN and 33 opened new positions — a net loss of 24 holders — while 74 trimmed existing stakes and 91 added.
The largest buyer was Glenview Capital Management, adding an estimated $53.4M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $60M sold.
- 221 institutional investors held Myriad Genetics (MYGN) as of Q4 2024, down from 246 in Q3 2024.
- Funds reported $1.27B of Myriad Genetics stock for Q4 2024, down 49% quarter-over-quarter.
- 33 funds opened new Myriad Genetics positions in Q4 2024 and 57 closed out, a net change of -24 holders.
- The largest Myriad Genetics buyer in Q4 2024 was Glenview Capital Management, an estimated $53.4M added.
- The largest Myriad Genetics seller in Q4 2024 was Loomis, Sayles & Company, an estimated $60M sold.
Based on aggregated 13F filings for Q4 2024.